Review





Similar Products

scl ab  (Amgen)
86
Amgen scl ab
Scl Ab, supplied by Amgen, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+scl/pm41927532-216-0-3?v=Amgen
Average 86 stars, based on 1 article reviews
scl ab - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier
anti lmo2  (Santa Cruz Biotechnology)
93
Santa Cruz Biotechnology anti lmo2
The LDB1 complex containing <t>LMO2</t> and GATA1 directly enhances the transcription of the Bcl11a gene. ( A-E ) ChIP-qPCR assays were performed to assess the occupancy of putative LDB1 complex component proteins, including LDB1, LMO2, GATA1, TAL1, and E2A, at the Bcl11a locus in E14.5 WT and KO FLCs. n = 3. Control, isotype control Ab; LDB1, anti-LDB1 Ab; <t>LMO2,</t> <t>anti-LMO2</t> Ab; GATA1, anti-GATA1 Ab; TAL1, anti-TAL1 Ab, E2A, anti-E2A Ab; WT, E14.5 FLCs; KO, E14.5 KO FLCs. Statistical significance was assessed by one-way ANOVA with Tukey HSD analysis. Mean values not sharing the same superscript letter ( a, b ) differ significantly at P < 0.05. ( F and G ) Dual-luciferase reporter assays were performed using the 210 bp region covering primer #3 ( Bcl11a intron #3) or the 225 bp region covering primer #4 ( Bcl11a intron #4) at Bcl11a locus. The relative luciferase activity of each construct containing either Bcl11a intron #3 or Bcl11a intron #4 was measured in HEK293T cells transfected with the indicated combination of each expression vector encoding Ldb1 , Lmo2 , or Gata1 cDNA. The schematic diagrams of each cloned enhancer region ( F ) and the results of the luciferase reporter assays ( G ) are presented. Ldb1 , expression vector encoding Ldb1 cDNA; Lmo2 , expression vector encoding Lmo2 cDNA; Gata1 , expression vector encoding Gata1 cDNA; ◯, transfected cells; ☓, untransfected cells. n = 5. Statistical significance was assessed by one-way ANOVA with Tukey HSD analysis. Mean values not sharing the same superscript letter ( a, b, c ) differ significantly at P < 0.05. ( H and I ) ChIP-qPCR assays were performed to assess LDB1 occupancy at the human BCL11A locus in K562 cells. The locations of each indicated primer set within the BCL11A locus are shown in the schematic diagram ( H ) along with the corresponding ChIP-qPCR results ( I ). n = 3. Mock K562, empty vector transfected K562 cells; KO K562, human LDB1 knockout K562 cells; Control, isotype control Ab; LDB1, anti-LDB1 Ab. Statistical significance was assessed by two-tailed Student's t -test. ∗ P < 0.05. All data are presented as the mean ± SEM.
Anti Lmo2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+scl/pmc12907011-138-44-45?v=Santa+Cruz+Biotechnology
Average 93 stars, based on 1 article reviews
anti lmo2 - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
anti tal1  (Santa Cruz Biotechnology)
93
Santa Cruz Biotechnology anti tal1
The LDB1 complex containing LMO2 and GATA1 directly enhances the transcription of the Bcl11a gene. ( A-E ) ChIP-qPCR assays were performed to assess the occupancy of putative LDB1 complex component proteins, including LDB1, LMO2, GATA1, <t>TAL1,</t> and E2A, at the Bcl11a locus in E14.5 WT and KO FLCs. n = 3. Control, isotype control Ab; LDB1, anti-LDB1 Ab; LMO2, anti-LMO2 Ab; GATA1, anti-GATA1 Ab; <t>TAL1,</t> <t>anti-TAL1</t> Ab, E2A, anti-E2A Ab; WT, E14.5 FLCs; KO, E14.5 KO FLCs. Statistical significance was assessed by one-way ANOVA with Tukey HSD analysis. Mean values not sharing the same superscript letter ( a, b ) differ significantly at P < 0.05. ( F and G ) Dual-luciferase reporter assays were performed using the 210 bp region covering primer #3 ( Bcl11a intron #3) or the 225 bp region covering primer #4 ( Bcl11a intron #4) at Bcl11a locus. The relative luciferase activity of each construct containing either Bcl11a intron #3 or Bcl11a intron #4 was measured in HEK293T cells transfected with the indicated combination of each expression vector encoding Ldb1 , Lmo2 , or Gata1 cDNA. The schematic diagrams of each cloned enhancer region ( F ) and the results of the luciferase reporter assays ( G ) are presented. Ldb1 , expression vector encoding Ldb1 cDNA; Lmo2 , expression vector encoding Lmo2 cDNA; Gata1 , expression vector encoding Gata1 cDNA; ◯, transfected cells; ☓, untransfected cells. n = 5. Statistical significance was assessed by one-way ANOVA with Tukey HSD analysis. Mean values not sharing the same superscript letter ( a, b, c ) differ significantly at P < 0.05. ( H and I ) ChIP-qPCR assays were performed to assess LDB1 occupancy at the human BCL11A locus in K562 cells. The locations of each indicated primer set within the BCL11A locus are shown in the schematic diagram ( H ) along with the corresponding ChIP-qPCR results ( I ). n = 3. Mock K562, empty vector transfected K562 cells; KO K562, human LDB1 knockout K562 cells; Control, isotype control Ab; LDB1, anti-LDB1 Ab. Statistical significance was assessed by two-tailed Student's t -test. ∗ P < 0.05. All data are presented as the mean ± SEM.
Anti Tal1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+scl/pmc12907011-138-39-40?v=Santa+Cruz+Biotechnology
Average 93 stars, based on 1 article reviews
anti tal1 - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
sclerostin scl ab  (Amgen)
86
Amgen sclerostin scl ab
(A) Female 22-month-old mice were treated on days 1 and 4 with antibody (12.5 mg/kg Scl-Ab + 12.5 mg/kg Dkk1-Ab; subcutaneously) or vehicle, and loaded on days 1-5. Gene expression analysis was performed by RT-qPCR 4 hours following the last loading bout for osteogenic genes (B) Bmp2 , (C) Sp7 , and (D) Col1a1 , and Wnt-related genes (E) Wnt1 , (F) <t>Sost</t> , and (G) Dkk1 . Two-factor repeated measures ANOVA was used to evaluate the main effects of loading (“Load”), dual antibody treatment (“Rx”), and their interaction. A significant loading-treatment interaction (“Int”) indicated that the transcriptional response to loading was differentially affected by treatment. Sidak test post hoc ANOVA was used for pairwise comparisons. (n=7-10 per group; 2-way repeated measures ANOVA with Šídák’s post-hoc test). All data shown as mean ± SD. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001, ns p>0.05.
Sclerostin Scl Ab, supplied by Amgen, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+scl/bio_rxiv__64898__2026__02__23__707532-49-6-18?v=Amgen
Average 86 stars, based on 1 article reviews
sclerostin scl ab - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier

Image Search Results


The LDB1 complex containing LMO2 and GATA1 directly enhances the transcription of the Bcl11a gene. ( A-E ) ChIP-qPCR assays were performed to assess the occupancy of putative LDB1 complex component proteins, including LDB1, LMO2, GATA1, TAL1, and E2A, at the Bcl11a locus in E14.5 WT and KO FLCs. n = 3. Control, isotype control Ab; LDB1, anti-LDB1 Ab; LMO2, anti-LMO2 Ab; GATA1, anti-GATA1 Ab; TAL1, anti-TAL1 Ab, E2A, anti-E2A Ab; WT, E14.5 FLCs; KO, E14.5 KO FLCs. Statistical significance was assessed by one-way ANOVA with Tukey HSD analysis. Mean values not sharing the same superscript letter ( a, b ) differ significantly at P < 0.05. ( F and G ) Dual-luciferase reporter assays were performed using the 210 bp region covering primer #3 ( Bcl11a intron #3) or the 225 bp region covering primer #4 ( Bcl11a intron #4) at Bcl11a locus. The relative luciferase activity of each construct containing either Bcl11a intron #3 or Bcl11a intron #4 was measured in HEK293T cells transfected with the indicated combination of each expression vector encoding Ldb1 , Lmo2 , or Gata1 cDNA. The schematic diagrams of each cloned enhancer region ( F ) and the results of the luciferase reporter assays ( G ) are presented. Ldb1 , expression vector encoding Ldb1 cDNA; Lmo2 , expression vector encoding Lmo2 cDNA; Gata1 , expression vector encoding Gata1 cDNA; ◯, transfected cells; ☓, untransfected cells. n = 5. Statistical significance was assessed by one-way ANOVA with Tukey HSD analysis. Mean values not sharing the same superscript letter ( a, b, c ) differ significantly at P < 0.05. ( H and I ) ChIP-qPCR assays were performed to assess LDB1 occupancy at the human BCL11A locus in K562 cells. The locations of each indicated primer set within the BCL11A locus are shown in the schematic diagram ( H ) along with the corresponding ChIP-qPCR results ( I ). n = 3. Mock K562, empty vector transfected K562 cells; KO K562, human LDB1 knockout K562 cells; Control, isotype control Ab; LDB1, anti-LDB1 Ab. Statistical significance was assessed by two-tailed Student's t -test. ∗ P < 0.05. All data are presented as the mean ± SEM.

Journal: Redox Biology

Article Title: LDB1 represses fetal hemoglobin expression by enhancing BCL11A transcription

doi: 10.1016/j.redox.2026.104070

Figure Lengend Snippet: The LDB1 complex containing LMO2 and GATA1 directly enhances the transcription of the Bcl11a gene. ( A-E ) ChIP-qPCR assays were performed to assess the occupancy of putative LDB1 complex component proteins, including LDB1, LMO2, GATA1, TAL1, and E2A, at the Bcl11a locus in E14.5 WT and KO FLCs. n = 3. Control, isotype control Ab; LDB1, anti-LDB1 Ab; LMO2, anti-LMO2 Ab; GATA1, anti-GATA1 Ab; TAL1, anti-TAL1 Ab, E2A, anti-E2A Ab; WT, E14.5 FLCs; KO, E14.5 KO FLCs. Statistical significance was assessed by one-way ANOVA with Tukey HSD analysis. Mean values not sharing the same superscript letter ( a, b ) differ significantly at P < 0.05. ( F and G ) Dual-luciferase reporter assays were performed using the 210 bp region covering primer #3 ( Bcl11a intron #3) or the 225 bp region covering primer #4 ( Bcl11a intron #4) at Bcl11a locus. The relative luciferase activity of each construct containing either Bcl11a intron #3 or Bcl11a intron #4 was measured in HEK293T cells transfected with the indicated combination of each expression vector encoding Ldb1 , Lmo2 , or Gata1 cDNA. The schematic diagrams of each cloned enhancer region ( F ) and the results of the luciferase reporter assays ( G ) are presented. Ldb1 , expression vector encoding Ldb1 cDNA; Lmo2 , expression vector encoding Lmo2 cDNA; Gata1 , expression vector encoding Gata1 cDNA; ◯, transfected cells; ☓, untransfected cells. n = 5. Statistical significance was assessed by one-way ANOVA with Tukey HSD analysis. Mean values not sharing the same superscript letter ( a, b, c ) differ significantly at P < 0.05. ( H and I ) ChIP-qPCR assays were performed to assess LDB1 occupancy at the human BCL11A locus in K562 cells. The locations of each indicated primer set within the BCL11A locus are shown in the schematic diagram ( H ) along with the corresponding ChIP-qPCR results ( I ). n = 3. Mock K562, empty vector transfected K562 cells; KO K562, human LDB1 knockout K562 cells; Control, isotype control Ab; LDB1, anti-LDB1 Ab. Statistical significance was assessed by two-tailed Student's t -test. ∗ P < 0.05. All data are presented as the mean ± SEM.

Article Snippet: Sheared chromatin was immunoprecipitated using 2 μg of the following Abs per sample: anti-LDB1 (Santa Cruz Biotechnology sc-365074) and its isotype control (R&D Systems MAB004), anti-GATA1 (Santa Cruz Biotechnology sc-265) and its isotype control (Santa Cruz Biotechnology, Inc. sc-3883), anti-TAL1 (Santa Cruz Biotechnology sc-393287), anti-LMO2 (Santa Cruz Biotechnology sc-65736), anti-E2A (Santa Cruz Biotechnology sc-416) and their isotype control (Thermo Fisher Scientific 14-4714-85).

Techniques: ChIP-qPCR, Control, Luciferase, Activity Assay, Construct, Transfection, Expressing, Plasmid Preparation, Clone Assay, Knock-Out, Two Tailed Test

The LDB1 complex containing LMO2 and GATA1 directly enhances the transcription of the Bcl11a gene. ( A-E ) ChIP-qPCR assays were performed to assess the occupancy of putative LDB1 complex component proteins, including LDB1, LMO2, GATA1, TAL1, and E2A, at the Bcl11a locus in E14.5 WT and KO FLCs. n = 3. Control, isotype control Ab; LDB1, anti-LDB1 Ab; LMO2, anti-LMO2 Ab; GATA1, anti-GATA1 Ab; TAL1, anti-TAL1 Ab, E2A, anti-E2A Ab; WT, E14.5 FLCs; KO, E14.5 KO FLCs. Statistical significance was assessed by one-way ANOVA with Tukey HSD analysis. Mean values not sharing the same superscript letter ( a, b ) differ significantly at P < 0.05. ( F and G ) Dual-luciferase reporter assays were performed using the 210 bp region covering primer #3 ( Bcl11a intron #3) or the 225 bp region covering primer #4 ( Bcl11a intron #4) at Bcl11a locus. The relative luciferase activity of each construct containing either Bcl11a intron #3 or Bcl11a intron #4 was measured in HEK293T cells transfected with the indicated combination of each expression vector encoding Ldb1 , Lmo2 , or Gata1 cDNA. The schematic diagrams of each cloned enhancer region ( F ) and the results of the luciferase reporter assays ( G ) are presented. Ldb1 , expression vector encoding Ldb1 cDNA; Lmo2 , expression vector encoding Lmo2 cDNA; Gata1 , expression vector encoding Gata1 cDNA; ◯, transfected cells; ☓, untransfected cells. n = 5. Statistical significance was assessed by one-way ANOVA with Tukey HSD analysis. Mean values not sharing the same superscript letter ( a, b, c ) differ significantly at P < 0.05. ( H and I ) ChIP-qPCR assays were performed to assess LDB1 occupancy at the human BCL11A locus in K562 cells. The locations of each indicated primer set within the BCL11A locus are shown in the schematic diagram ( H ) along with the corresponding ChIP-qPCR results ( I ). n = 3. Mock K562, empty vector transfected K562 cells; KO K562, human LDB1 knockout K562 cells; Control, isotype control Ab; LDB1, anti-LDB1 Ab. Statistical significance was assessed by two-tailed Student's t -test. ∗ P < 0.05. All data are presented as the mean ± SEM.

Journal: Redox Biology

Article Title: LDB1 represses fetal hemoglobin expression by enhancing BCL11A transcription

doi: 10.1016/j.redox.2026.104070

Figure Lengend Snippet: The LDB1 complex containing LMO2 and GATA1 directly enhances the transcription of the Bcl11a gene. ( A-E ) ChIP-qPCR assays were performed to assess the occupancy of putative LDB1 complex component proteins, including LDB1, LMO2, GATA1, TAL1, and E2A, at the Bcl11a locus in E14.5 WT and KO FLCs. n = 3. Control, isotype control Ab; LDB1, anti-LDB1 Ab; LMO2, anti-LMO2 Ab; GATA1, anti-GATA1 Ab; TAL1, anti-TAL1 Ab, E2A, anti-E2A Ab; WT, E14.5 FLCs; KO, E14.5 KO FLCs. Statistical significance was assessed by one-way ANOVA with Tukey HSD analysis. Mean values not sharing the same superscript letter ( a, b ) differ significantly at P < 0.05. ( F and G ) Dual-luciferase reporter assays were performed using the 210 bp region covering primer #3 ( Bcl11a intron #3) or the 225 bp region covering primer #4 ( Bcl11a intron #4) at Bcl11a locus. The relative luciferase activity of each construct containing either Bcl11a intron #3 or Bcl11a intron #4 was measured in HEK293T cells transfected with the indicated combination of each expression vector encoding Ldb1 , Lmo2 , or Gata1 cDNA. The schematic diagrams of each cloned enhancer region ( F ) and the results of the luciferase reporter assays ( G ) are presented. Ldb1 , expression vector encoding Ldb1 cDNA; Lmo2 , expression vector encoding Lmo2 cDNA; Gata1 , expression vector encoding Gata1 cDNA; ◯, transfected cells; ☓, untransfected cells. n = 5. Statistical significance was assessed by one-way ANOVA with Tukey HSD analysis. Mean values not sharing the same superscript letter ( a, b, c ) differ significantly at P < 0.05. ( H and I ) ChIP-qPCR assays were performed to assess LDB1 occupancy at the human BCL11A locus in K562 cells. The locations of each indicated primer set within the BCL11A locus are shown in the schematic diagram ( H ) along with the corresponding ChIP-qPCR results ( I ). n = 3. Mock K562, empty vector transfected K562 cells; KO K562, human LDB1 knockout K562 cells; Control, isotype control Ab; LDB1, anti-LDB1 Ab. Statistical significance was assessed by two-tailed Student's t -test. ∗ P < 0.05. All data are presented as the mean ± SEM.

Article Snippet: Sheared chromatin was immunoprecipitated using 2 μg of the following Abs per sample: anti-LDB1 (Santa Cruz Biotechnology sc-365074) and its isotype control (R&D Systems MAB004), anti-GATA1 (Santa Cruz Biotechnology sc-265) and its isotype control (Santa Cruz Biotechnology, Inc. sc-3883), anti-TAL1 (Santa Cruz Biotechnology sc-393287), anti-LMO2 (Santa Cruz Biotechnology sc-65736), anti-E2A (Santa Cruz Biotechnology sc-416) and their isotype control (Thermo Fisher Scientific 14-4714-85).

Techniques: ChIP-qPCR, Control, Luciferase, Activity Assay, Construct, Transfection, Expressing, Plasmid Preparation, Clone Assay, Knock-Out, Two Tailed Test

(A) Female 22-month-old mice were treated on days 1 and 4 with antibody (12.5 mg/kg Scl-Ab + 12.5 mg/kg Dkk1-Ab; subcutaneously) or vehicle, and loaded on days 1-5. Gene expression analysis was performed by RT-qPCR 4 hours following the last loading bout for osteogenic genes (B) Bmp2 , (C) Sp7 , and (D) Col1a1 , and Wnt-related genes (E) Wnt1 , (F) Sost , and (G) Dkk1 . Two-factor repeated measures ANOVA was used to evaluate the main effects of loading (“Load”), dual antibody treatment (“Rx”), and their interaction. A significant loading-treatment interaction (“Int”) indicated that the transcriptional response to loading was differentially affected by treatment. Sidak test post hoc ANOVA was used for pairwise comparisons. (n=7-10 per group; 2-way repeated measures ANOVA with Šídák’s post-hoc test). All data shown as mean ± SD. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001, ns p>0.05.

Journal: bioRxiv

Article Title: Combination Treatment with Sclerostin and Dkk1 Antibodies Synergizes with Tibial Loading to Stimulate Bone Formation in Aged Mice

doi: 10.64898/2026.02.23.707532

Figure Lengend Snippet: (A) Female 22-month-old mice were treated on days 1 and 4 with antibody (12.5 mg/kg Scl-Ab + 12.5 mg/kg Dkk1-Ab; subcutaneously) or vehicle, and loaded on days 1-5. Gene expression analysis was performed by RT-qPCR 4 hours following the last loading bout for osteogenic genes (B) Bmp2 , (C) Sp7 , and (D) Col1a1 , and Wnt-related genes (E) Wnt1 , (F) Sost , and (G) Dkk1 . Two-factor repeated measures ANOVA was used to evaluate the main effects of loading (“Load”), dual antibody treatment (“Rx”), and their interaction. A significant loading-treatment interaction (“Int”) indicated that the transcriptional response to loading was differentially affected by treatment. Sidak test post hoc ANOVA was used for pairwise comparisons. (n=7-10 per group; 2-way repeated measures ANOVA with Šídák’s post-hoc test). All data shown as mean ± SD. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001, ns p>0.05.

Article Snippet: Antibody-treated mice received a combination of Sclerostin (Scl-Ab) and Dkk1 (Dkk1-Ab) monoclonal antibodies (provided as a gift by Amgen) at a dose of 12.5 mg/kg each, as previously described ( ) .

Techniques: Gene Expression, Quantitative RT-PCR